Working… Menu

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03926130
Recruitment Status : Recruiting
First Posted : April 24, 2019
Last Update Posted : June 9, 2021
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

Condition or disease Intervention/treatment Phase
Crohn's Disease Drug: Mirikizumab Drug: Ustekinumab Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Actual Study Start Date : July 23, 2019
Estimated Primary Completion Date : December 23, 2022
Estimated Study Completion Date : April 21, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Ustekinumab

Arm Intervention/treatment
Experimental: Mirikizumab

Mirikizumab given intravenously (IV) and subcutaneously (SC).

Participants in the open-label adolescent addendum will be given mirikizumab IV and SC.

Drug: Mirikizumab
Administered IV
Other Name: LY3074828

Drug: Mirikizumab
Administered SC
Other Name: LY3074828

Active Comparator: Ustekinumab
Ustekinumab given IV and SC.
Drug: Ustekinumab
Administered IV

Drug: Ustekinumab
Administered SC

Placebo Comparator: Placebo
Placebo given IV and SC.
Drug: Placebo
Administered IV

Drug: Placebo
Administered SC

Primary Outcome Measures :
  1. Percentage of Participants Achieving Endoscopic Response [ Time Frame: Week 52 ]
    Endoscopic response based on Simple Endoscopic Score for Crohn's Disease (SES-CD) total score

  2. Percentage of Participants Achieving Clinical Remission [ Time Frame: Week 52 ]
    Clinical remission by Patient Reported Outcome (PRO) based on stool frequency (SF) and abdominal pain (AP)

Secondary Outcome Measures :
  1. Percentage of Participants Achieving Endoscopic Remission [ Time Frame: Week 52 ]
    Endoscopic remission based on SES-CD total score

  2. Percentage of Participants Achieving Clinical Remission or Endoscopic Remission who were Corticosteroid Free [ Time Frame: Week 52 ]
    Clinical remission by PRO based on SF and AP and endoscopic remission based on SES-CD total score

  3. Percentage of Participants Achieving Clinical Remission [ Time Frame: Week 12 ]
    Clinical remission by PRO is based on SF and AP

  4. Percentage of Participants Achieving Clinical Remission [ Time Frame: Week 52 ]
    Clinical remission based on CDAI

  5. Change from Baseline in C-Reactive Protein [ Time Frame: Baseline, Week 52 ]
    Change from baseline in C-Reactive Protein

  6. Change from Baseline in Fecal Calprotectin [ Time Frame: Baseline, Week 52 ]
    Change from baseline in fecal calprotectin

  7. Percentage of Participants with Extraintestinal Manifestations (EIMs) of Crohn's Disease [ Time Frame: Week 52 ]
    Percentage of participants with EIMs of Crohn's Disease

  8. Percentage of Participants with Fistulae Response [ Time Frame: Week 52 ]
    Percentage of participants with fistulae response

  9. Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Mirikizumab [ Time Frame: Baseline through Week 52 ]
    PK: AUC of mirikizumab

  10. Change from Baseline in Health Related Quality of Life [ Time Frame: Baseline, Week 52 ]
    Health related quality of life based on Inflammatory Bowel Disease Questionnaire (IBDQ) score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of CD for at least 3 months prior to baseline
  • Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD
  • Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD
  • If female, subject must meet the contraception recommendations

Exclusion Criteria:

  • Have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome
  • Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery
  • Have a stoma, ileoanal pouch or ostomy
  • Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline
  • Have ever received any monoclonal antibodies binding IL-23

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03926130

Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Show Show 655 study locations
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Additional Information:
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT03926130    
Other Study ID Numbers: 16590
I6T-MC-AMAM ( Other Identifier: Eli Lilly and Company )
2018-004614-18 ( EudraCT Number )
First Posted: April 24, 2019    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Dermatologic Agents